세계의 이식용 HLA 타이핑 시장 : 제품 및 서비스, 기술, 시퀀싱, 제품, 용도, 이식 유형, 최종 사용자 및 지역별 - 예측(-2028년)

HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Kits, Software), Application (Antibody Screening), Type (Organ Transplant, Tissue), End User, and Region - Global Forecast to 2028

US $ 4,950 ￦ 7,024,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,437,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,565,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,191,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 이식용 HLA 타이핑 시장 규모는 6.3%의 CAGR로 확대되어 2023년 8억 달러에서 2028년 11억 달러에 달할 것으로 예상됩니다.

HLA 타이핑 분야의 기술 발전, 이식 수요 증가, 장기 기증을 장려하는 정부의 이니셔티브 증가, HLA 타이핑 분야의 연구 활동 증가 등이 시장 성장을 견인하고 있습니다.

조사범위
대상범위	2021-2028년
기준년도	2022년
예측 기간	2023-2028년
단위	달러
부문	제품 및 서비스, 기술, 응용 분야, 최종 사용자, 지역
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

최종 사용자별로 보면, 2022년 이식용 HLA 타이핑 시장에서 독립적인 참조 연구소가 가장 큰 점유율을 차지할 것으로 예상됩니다. 그 배경에는 생명공학 기업의 HLA 타이핑 서비스 아웃소싱에 대한 진단 기관의 선호도 증가, 고해상도 분자 기술의 존재, 레퍼런스 연구소와 이식 센터 간의 협력 관계 증가 등이 있습니다.

기술별로는 분자 분석 기술 분야가 2022년 이식용 HLA 타이핑 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 이는 HLA 타이핑을 위한 분자 기술의 최종 사용자 채택이 꾸준히 증가하고 있으며, 제조업체들이 분자 기술의 고해상도 분석법 개발에 집중하고 있기 때문입니다.

2022년 이식용 HLA 타이핑 시장에서 북미가 가장 큰 점유율을 차지할 것으로 예상되며, 유럽이 그 뒤를 이었습니다. 이는 주로 고급 진단 기술의 가용성, 제조업체의 존재감 증가, 의료 인프라가 잘 구축되어 있기 때문인 것으로 보입니다.

또한, 새로운 HLA 대립유전자 연구에 종사하는 저명한 생명공학 기업의 존재, 이식율 증가, 유리한 상환 정책 등이 이 지역 시장 성장을 뒷받침하고 있습니다.

이 보고서는 세계 이식용 HLA 타이핑 시장을 조사했으며, 제품 및 서비스별/기술별/시퀀싱별/제품별/용도별/이식 유형별/최종사용자별/지역별 동향, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 가격 분석
• 특허 분석
• 밸류체인 분석
• 공급망 분석
• 생태계 매핑
• Porter의 Five Forces 분석
• 상환 시나리오
• 규제 상황
• 2023년-2025년 주요 컨퍼런스 및 이벤트
• 고객의 비즈니스에 영향을 미치는 동향/혼란
• 무역 분석
• 주요 이해관계자와 구입 기준

제6장 이식용 HLA 타이핑 시장, 제품 및 서비스별

• 서론
• 시약 및 소모품
• 장비
• 소프트웨어 및 서비스

제7장 이식용 HLA 타이핑 시장, 기술별

• 서론
• 분자 어세이 기술
• 비분자 어세이 기술

제8장 이식용 HLA 타이핑 시장, 용도별

• 서론
• 진단
• 연구

제9장 이식용 HLA 타이핑 시장, 이식 유형별

• 서론
• 고형 장기 이식
• 연부 조직 이식

제10장 이식용 HLA 타이핑 시장, 최종사용자별

• 서론
• 독립계 표준검사실
• 병원 및 이식 센터
• 학술기관 및 연구기관

제11장 이식용 HLA 타이핑 시장, 지역별

• 서론
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제12장 경쟁 구도

• 개요
• 주요 시장 진출기업의 전략/유력 기업
• 매출 점유율 분석(2022년)
• 시장 순위 점유율
• 주요 기업 기업 평가 매트릭스(2022년)
• 스타트업/중소기업 기업 평가 매트릭스(2022년)
• 경쟁 벤치마킹
• 경쟁 시나리오

제13장 기업 개요

• 주요 시장 진출기업
  • THERMO FISHER SCIENTIFIC
  • ILLUMINA, INC.
  • QIAGEN
  • BIO-RAD LABORATORIES, INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • CAREDX
  • IMMUCOR, INC.
  • LUMINEX CORPORATION(DIASORIN)
  • TBG DIAGNOSTICS LIMITED
  • FUJIREBIO
  • OMIXON, INC.
  • GENDX
  • BAG DIAGNOSTICS GMBH
  • CREATIVE BIOLABS
  • PACBIO
• 기타 기업
  • HISTOGENETICS LLC
  • SCISCO GENETICS, INC.
  • INNO-TRAIN DIAGNOSTIK GMBH
  • BIONOBIS
  • QUEST DIAGNOSTICS
  • SCIENCELL RESEARCH LABORATORIES, INC.
  • BGI GENOMICS
  • CEGAT GMBH
  • PROIMMUNE LTD.
  • CD GENOMICS

제14장 부록

LSH

영문 목차

영문목차

The global HLA typing for the transplants market is expected to reach USD 1.1 billion by 2028 from USD 0.8 billion in 2023, at a CAGR of 6.3%. Rising technological advancements in the field of HLA typing, increasing demand for transplantation, rising initiatives by the government to boost the organ donation, and increasing research activities in field of HLA typing to support the market growth.

Scope of the Report
Years Considered for the Study	2021-2028
Base Year	2022
Forecast Period	2023-2028
Units Considered	Value (USD) billion
Segments	Product & Service, technology, application, end-user, and region
Regions covered	North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

"The independent reference laboratories segment accounted for the largest share of the HLA typing for transplants market, by end-user, in 2022."

Based on end user, the HLA typing for transplants market is segmented into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2022, independent reference laboratories accounted for the largest share of the HLA typing for transplants . This is attributed the growing preference of diagnostic laboratories to outsource the HLA typing services by biotechnology companies, presence of high resolution molecular technology , and increasing collaboration among reference laboratories and transplant centers

"The molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market, by technology, in 2022."

The HLA typing for transplants market, by technology, is segmented into non-molecular and molecular assay technologies. In 2022, the molecular assay technologies segment accounted for the largest share of the HLA typing for transplants market. This is attributed to the strong adoption of molecular technology for HLA typing among end user setting and strong focus of manufacturers towards the development of high resolution assays for the molecular technologies

"North America accounted for the largest share of the HLA typing for transplants market in 2022."

North America accounted for the largest share of the HLA typing for transplants market in 2022, followed by Europe. This can primarily be availability of advanced diagnostic technology, increased presence of manufacturers, and well established healthcare infrastructure.

Additionally, presence of prominent biotechnology companies engaged in the research of new HLA alleles, increasing transplantation rates, and favorable reimbursement policy to support the growth of market in the region

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1 (48%), Tier 2 (36%), and Tier 3 (16%)
• By Designation: C-level (10%), Director-level (14%), and Others (76%)
• By Region: North America (40%), Europe (32%), APAC (20%), Latin America (5%) and MEA (3%)

Some of the prominent players in the HLA typing for transplants market are Thermo Fisher Scientific, Inc. (US), QIAGEN (Germany), Illumina (US), CareDx, Inc. (US), Immucor, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Luminex Corporation(US)

Research Coverage

This report studies the HLA typing for transplants market based on product& service, technology, transplant type, application, end-user, and region. It studies major factors (such as drivers and restraints) affecting market growth. The report also analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. It the the with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of market segments with respect to five major regions and their respective major countries.

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

• Analysis of key drivers ( increasing transplantation rates, growing technological advancements, increasing government initiatives to boost HLA typing services in transplantation) restraints (high cost of molecular test use in HLA typing procedures), opportunities (technological shift from non-molecular serological assay to molecular assay, high growth offered by emerging markets), and challenges (Significant gap between number of organ donors and transplant recipients) influencing the growth of HLA typing for transplant market
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the HLA typing for transplant market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the HLA typing for transplant market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the HLA typing for transplant market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 REGIONS COVERED
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 KEY STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES
• 1.6 RECESSION IMPACT: HLA TYPING FOR TRANSPLANTS MARKET

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 1 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY RESEARCH
    • 2.1.2.1 Key data from primary sources
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 GLOBAL HLA TYPING FOR TRANSPLANTS MARKET: BREAKDOWN OF PRIMARIES
• 2.2 MARKET SIZE ESTIMATION METHODOLOGY
  • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
  • 2.2.2 PROCEDURE-BASED MARKET ESTIMATION
  • FIGURE 5 MARKET SIZE ESTIMATION: HLA TYPING FOR TRANSPLANTS MARKET
  • 2.2.3 PRIMARY RESEARCH VALIDATION
• 2.3 DATA TRIANGULATION
  • FIGURE 6 DATA TRIANGULATION METHODOLOGY
• 2.4 RESEARCH ASSUMPTIONS AND LIMITATIONS
  • 2.4.1 RESEARCH ASSUMPTIONS
  • 2.4.2 RESEARCH LIMITATIONS
• 2.5 RECESSION IMPACT ANALYSIS
  • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)

3 EXECUTIVE SUMMARY

• FIGURE 7 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE, 2023 VS. 2028
• FIGURE 8 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
• FIGURE 9 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
• FIGURE 10 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC SNAPSHOT (2022)

4 PREMIUM INSIGHTS

• 4.1 HLA TYPING FOR TRANSPLANTS MARKET OVERVIEW
  • FIGURE 11 INCREASING NUMBER OF TRANSPLANT PROCEDURES TO DRIVE MARKET
• 4.2 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY PRODUCT & SERVICE & COUNTRY (2022)
  • FIGURE 12 REAGENTS & CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
• 4.3 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
  • FIGURE 13 MOLECULAR ASSAY TECHNOLOGIES SEGMENT TO RETAIN DOMINANCE TILL 2028
• 4.4 MOLECULAR ASSAY TECHNOLOGIES MARKET, 2023 VS. 2028
  • FIGURE 14 NGS TO REGISTER HIGHEST GROWTH
• 4.5 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY END USER, 2023 VS. 2028 (USD MILLION)
  • FIGURE 15 INDEPENDENT REFERENCE LABORATORY SEGMENT TO DOMINATE MARKET TILL 2028
• 4.6 HLA TYPING FOR TRANSPLANTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 16 CHINA TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 17 HLA TYPING FOR TRANSPLANTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing number of transplant procedures globally
    • 5.2.1.2 Technological advancements in HLA typing
    • 5.2.1.3 Government initiatives to boost HLA typing services in transplantation
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of molecular tests used for HLA typing
  • TABLE 2 COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2022)
    • 5.2.2.2 Limited reimbursements for target procedures in emerging countries
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising adoption of cross-matching and chimerism testing pre/post-transplantation
    • 5.2.3.2 Technological shift from non-molecular serological assays to gene-based HLA profiling
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Significant gap in organ demand and supply
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
  • TABLE 3 INDICATIVE PRICING FOR HLA TYPING INSTRUMENTS, REAGENTS, AND KITS FOR TRANSPLANTATION
  • 5.3.2 AVERAGE SELLING PRICE OF HLA TYPING INSTRUMENTS, BY KEY PLAYER
  • TABLE 4 AVERAGE SELLING PRICE OF HLA TYPING FOR TRANSPLANT PRODUCTS
• 5.4 PATENT ANALYSIS
  • FIGURE 18 PATENT ANALYSIS OF NEXT-GENERATION SEQUENCING TECHNOLOGIES
• 5.5 VALUE CHAIN ANALYSIS
  • FIGURE 19 VALUE CHAIN ANALYSIS OF HLA TYPING FOR TRANSPLANTS MARKET: MAJOR VALUE-ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
• 5.6 SUPPLY CHAIN ANALYSIS
  • FIGURE 20 HLA TYPING FOR TRANSPLANTS MARKET: SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM MAPPING
  • FIGURE 21 HLA TYPING FOR TRANSPLANTS MARKET: ECOSYSTEM MAP
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 5 HLA TYPING FOR TRANSPLANTS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF BUYERS
  • 5.8.4 BARGAINING POWER OF SUPPLIERS
  • 5.8.5 DEGREE OF COMPETITION
• 5.9 REIMBURSEMENT SCENARIO
  • TABLE 6 CPT CODES FOR MOLECULAR DIAGNOSTICS: HLA TESTING FOR TRANSPLANT HISTOCOMPATIBILITY
• 5.10 REGULATORY LANDSCAPE
  • TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.1 NORTH AMERICA
    • 5.10.1.1 US
    • 5.10.1.2 Canada
  • 5.10.2 EUROPE
  • 5.10.3 ASIA PACIFIC
    • 5.10.3.1 China
    • 5.10.3.2 Japan
  • TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.10.3.3 India
  • 5.10.4 LATIN AMERICA
    • 5.10.4.1 Brazil
  • 5.10.5 MIDDLE EAST
• 5.11 KEY CONFERENCES & EVENTS, 2023-2025
  • TABLE 12 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023-2025
• 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 22 REVENUE SHIFT IN HLA TYPING FOR TRANSPLANTS MARKET
• 5.13 TRADE ANALYSIS
  • 5.13.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
  • TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS
  • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MARKET PRODUCTS (%)
  • 5.14.2 BUYING CRITERIA
  • FIGURE 24 KEY BUYING CRITERIA FOR MARKET PRODUCTS
  • TABLE 16 KEY BUYING CRITERIA FOR HLA TYPING FOR MARKET PRODUCTS

6 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
  • TABLE 17 HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
• 6.2 REAGENTS & CONSUMABLES
  • 6.2.1 REAGENTS & CONSUMABLES TO HOLD LARGEST MARKET SHARE
  • TABLE 18 HLA TYPING REAGENTS & CONSUMABLES MARKET, BY REGION, 2021-2028 (USD MILLION)
• 6.3 INSTRUMENTS
  • 6.3.1 ADVANCEMENTS IN HLA-BASED GENOME PROFILING TO SUPPORT SEGMENT GROWTH
  • TABLE 19 HLA TYPING INSTRUMENTS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 RISING DEMAND FOR INNOVATIVE SOFTWARE TO DRIVE MARKET
  • TABLE 20 HLA TYPING SOFTWARE & SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)

7 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
  • TABLE 21 HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
• 7.2 MOLECULAR ASSAY TECHNOLOGIES
  • TABLE 22 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 23 MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 7.2.1 PCR-BASED MOLECULAR ASSAYS
  • TABLE 24 PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 25 PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.1.1 Sequence-specific primer-PCR
      • 7.2.1.1.1 Growing public-private investments in research to support market growth
  • TABLE 26 SEQUENCE-SPECIFIC PRIMER-PCR MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.1.2 Sequence-specific oligonucleotide-PCR
      • 7.2.1.2.1 Growing awareness of benefits among medical professionals to drive demand
  • TABLE 27 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.1.3 Real-time PCR
      • 7.2.1.3.1 High cost of real-time PCR and procedural complexity to hamper market growth
  • TABLE 28 REAL-TIME PCR MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.1.4 Other PCR-based molecular assays
  • TABLE 29 OTHER PCR-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
  • TABLE 30 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 31 SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.2.1 Sanger sequencing
      • 7.2.2.1.1 Growing demand for high-throughput DNA sequencers to drive market
  • TABLE 32 SANGER SEQUENCING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.2.2 NGS
      • 7.2.2.2.1 High scalability, low turnaround time, and other advantages to boost adoption
  • TABLE 33 NGS MARKET, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.2.3 Other sequencing-based molecular assays
  • TABLE 34 OTHER SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
  • 7.3.1 REPLACEMENT OF NON-MOLECULAR TECHNIQUES WITH DNA-BASED HLA TYPING TO HAMPER MARKET GROWTH
  • TABLE 35 NON-MOLECULAR ASSAY TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)

8 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
  • TABLE 36 HLA TYPING FOR TRANSPLANTS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
• 8.2 DIAGNOSTIC APPLICATIONS
  • TABLE 37 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 38 HLA TYPING FOR TRANSPLANTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)
  • 8.2.1 ANTIBODY SCREENING
    • 8.2.1.1 Rising number of recipients for transplant procedures to drive market growth
  • TABLE 39 ANTIBODY SCREENING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 8.2.2 CHIMERISM MONITORING
    • 8.2.2.1 Rising trend of personalized transplant medicine for effective risk management to support market growth
  • TABLE 40 CHIMERISM MONITORING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 8.2.3 OTHER APPLICATIONS
  • TABLE 41 OTHER DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 8.3 RESEARCH APPLICATIONS
  • 8.3.1 RISING INVESTMENTS AND SUPPORT FOR RESEARCH TO DRIVE MARKET
  • TABLE 42 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

9 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE

• 9.1 INTRODUCTION
  • TABLE 43 HLA TYPING FOR TRANSPLANTS MARKET, BY TRANSPLANT TYPE, 2021-2028 (USD MILLION)
• 9.2 SOLID ORGAN TRANSPLANTS
  • 9.2.1 SOLID ORGAN TRANSPLANTS TO HOLD LARGEST MARKET SHARE
  • TABLE 44 HLA TYPING FOR SOLID ORGAN TRANSPLANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 9.3 SOFT TISSUE TRANSPLANTS
  • 9.3.1 INCREASING BLOOD CANCER PREVALENCE TO BOOST DEMAND
  • TABLE 45 HLA TYPING FOR SOFT TISSUE TRANSPLANTS MARKET, BY REGION, 2021-2028 (USD MILLION)

10 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER

• 10.1 INTRODUCTION
  • TABLE 46 HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021-2028 (USD MILLION)
• 10.2 INDEPENDENT REFERENCE LABORATORIES
  • 10.2.1 INDEPENDENT LABS TO HOLD LARGEST MARKET SHARE
  • TABLE 47 HLA TYPING FOR TRANSPLANTS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, 2021-2028 (USD MILLION)
• 10.3 HOSPITALS & TRANSPLANT CENTERS
  • 10.3.1 RISING TRANSPLANT VOLUMES TO DRIVE DEMAND FOR HLA TYPING
  • TABLE 48 HLA TYPING FOR TRANSPLANTS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, 2021-2028 (USD MILLION)
• 10.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
  • 10.4.1 RISING RESEARCH ACTIVITY TO DRIVE MARKET
  • TABLE 49 HLA TYPING FOR TRANSPLANTS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, 2021-2028 (USD MILLION)

11 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION

• 11.1 INTRODUCTION
  • TABLE 50 HLA TYPING FOR TRANSPLANTS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: RECESSION IMPACT
  • FIGURE 25 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
  • TABLE 51 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 52 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 53 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 54 NORTH AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.2.2 US
    • 11.2.2.1 US to hold largest market share
  • FIGURE 26 US: SOLID ORGAN TRANSPLANTATIONS PERFORMED, 2019-2021
  • TABLE 55 US: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 56 US: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 57 US: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 58 US: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.2.3 CANADA
    • 11.2.3.1 Rising availability of transplant diagnostic products to support market growth
  • TABLE 59 CANADA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 60 CANADA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 61 CANADA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 62 CANADA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
• 11.3 EUROPE
  • 11.3.1 EUROPE: RECESSION IMPACT
  • TABLE 63 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 64 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 65 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 66 EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.3.2 GERMANY
    • 11.3.2.1 Germany to dominate European HLA typing for transplants market
  • TABLE 67 GERMANY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 68 GERMANY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 69 GERMANY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 70 GERMANY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.3.3 UK
    • 11.3.3.1 Rising number of transplant procedures to drive market
  • TABLE 71 UK: NUMBER OF ORGAN TRANSPLANTATION PROCEDURES, 2019 VS. 2021
  • TABLE 72 UK: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 73 UK: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 74 UK: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 75 UK: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing adoption of MDx for donor-recipient compatibility testing to support market
  • TABLE 76 FRANCE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 77 FRANCE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 78 FRANCE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 79 FRANCE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.3.5 SPAIN
    • 11.3.5.1 Increasing solid organ transplantation procedures to drive market
  • TABLE 80 SPAIN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 81 SPAIN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 82 SPAIN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 83 SPAIN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.3.6 ITALY
    • 11.3.6.1 Slowdown in Italian healthcare sector to limit market growth
  • TABLE 84 ITALY: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 85 ITALY: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 86 ITALY: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 87 ITALY: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.3.7 REST OF EUROPE
  • TABLE 88 REST OF EUROPE: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 89 REST OF EUROPE: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 90 REST OF EUROPE: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 91 REST OF EUROPE: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
  • FIGURE 27 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET SNAPSHOT
  • TABLE 92 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 93 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.4.2 CHINA
    • 11.4.2.1 Healthcare infrastructural improvements to support market growth
  • TABLE 96 CHINA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 97 CHINA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 98 CHINA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 99 CHINA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.4.3 INDIA
    • 11.4.3.1 Increasing transplantation procedures to drive market
  • TABLE 100 INDIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 101 INDIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 102 INDIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 103 INDIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.4.4 JAPAN
    • 11.4.4.1 Significant growth in chronic disease prevalence to support market growth
  • TABLE 104 JAPAN: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 105 JAPAN: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 106 JAPAN: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 107 JAPAN: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Rising number of solid organ transplantation procedures to support market growth
  • TABLE 108 AUSTRALIA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 109 AUSTRALIA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 110 AUSTRALIA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 111 AUSTRALIA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Government support and medical coverage for transplantation to drive market
  • TABLE 112 SOUTH KOREA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 113 SOUTH KOREA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 114 SOUTH KOREA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 115 SOUTH KOREA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.4.7 REST OF ASIA PACIFIC
  • TABLE 116 REST OF ASIA PACIFIC: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 117 REST OF ASIA PACIFIC: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 118 REST OF ASIA PACIFIC: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 119 REST OF ASIA PACIFIC: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: RECESSION IMPACT
  • TABLE 120 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 121 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 122 LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 123 LATIN AMERICA HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to dominate LATAM market
  • TABLE 124 BRAZIL: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 125 BRAZIL: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 126 BRAZIL: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 127 BRAZIL: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising medical tourism to drive market
  • TABLE 128 MEXICO: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 129 MEXICO: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 130 MEXICO: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 131 MEXICO: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 11.5.4 REST OF LATIN AMERICA
  • TABLE 132 REST OF LATIN AMERICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 133 REST OF LATIN AMERICA: MOLECULAR ASSAY TECHNOLOGIES MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 134 REST OF LATIN AMERICA: PCR-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 135 REST OF LATIN AMERICA: SEQUENCING-BASED MOLECULAR ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 GOVERNMENT INITIATIVES AND RISING GERIATRIC POPULATION TO SUPPORT ADOPTION
  • 11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
  • TABLE 136 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • TABLE 137 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • TABLE 138 MIDDLE EAST & AFRICA: HLA TYPING FOR TRANSPLANTS MARKET, BY END USER, 2021-2028 (USD MILLION)

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET (2020 TO 2023)
• 12.3 REVENUE SHARE ANALYSIS (2022)
  • FIGURE 29 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN HLA TYPING FOR TRANSPLANTS MARKET, 2019-2022 (USD MILLION)
• 12.4 MARKET RANKING SHARE
  • FIGURE 30 HLA TYPING FOR TRANSPLANTS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 139 HLA TYPING FOR TRANSPLANTS MARKET: DEGREE OF COMPETITION
• 12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • FIGURE 31 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
• 12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 STARTING BLOCKS
  • 12.6.3 RESPONSIVE COMPANIES
  • 12.6.4 DYNAMIC COMPANIES
  • FIGURE 32 HLA TYPING FOR TRANSPLANTS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (AS OF 2022)
• 12.7 COMPETITIVE BENCHMARKING
  • FIGURE 33 COMPANY FOOTPRINT ANALYSIS: TOP FIVE PLAYERS
  • TABLE 140 PRODUCT & SERVICE FOOTPRINT ANALYSIS (TOP FIVE PLAYERS)
  • TABLE 141 REGIONAL FOOTPRINT ANALYSIS (TOP FIVE PLAYERS)
  • TABLE 142 HLA TYPING FOR TRANSPLANTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• 12.8 COMPETITIVE SCENARIO
  • 12.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
  • TABLE 143 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS (2020-2023)
  • 12.8.2 DEALS
  • TABLE 144 KEY DEALS (2020-2023)

13 COMPANY PROFILES

• (Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **
• 13.1 KEY PLAYERS
  • 13.1.1 THERMO FISHER SCIENTIFIC
  • TABLE 145 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
  • FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2022)
  • 13.1.2 ILLUMINA, INC.
  • TABLE 146 ILLUMINA, INC.: COMPANY OVERVIEW
  • FIGURE 35 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
  • 13.1.3 QIAGEN
  • TABLE 147 QIAGEN: COMPANY OVERVIEW
  • FIGURE 36 QIAGEN: COMPANY SNAPSHOT (2022)
  • 13.1.4 BIO-RAD LABORATORIES, INC.
  • TABLE 148 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • FIGURE 37 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
  • 13.1.5 F. HOFFMANN-LA ROCHE LTD.
  • TABLE 149 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • FIGURE 38 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022)
  • 13.1.6 CAREDX
  • TABLE 150 CAREDX: COMPANY OVERVIEW
  • FIGURE 39 CAREDX: COMPANY SNAPSHOT (2022)
  • 13.1.7 IMMUCOR, INC.
  • TABLE 151 IMMUCOR, INC.: COMPANY OVERVIEW
  • 13.1.8 LUMINEX CORPORATION (DIASORIN)
  • TABLE 152 DIASORIN S.P.A: COMPANY OVERVIEW
  • FIGURE 40 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
  • 13.1.9 TBG DIAGNOSTICS LIMITED
  • TABLE 153 TBG DIAGNOSTICS LIMITED: COMPANY OVERVIEW
  • FIGURE 41 TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2022)
  • 13.1.10 FUJIREBIO
  • TABLE 154 FUJIREBIO: COMPANY OVERVIEW
  • 13.1.11 OMIXON, INC.
  • TABLE 155 OMIXON, INC.: COMPANY OVERVIEW
  • 13.1.12 GENDX
  • TABLE 156 GENDX.: COMPANY OVERVIEW
  • 13.1.13 BAG DIAGNOSTICS GMBH
  • TABLE 157 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
  • 13.1.14 CREATIVE BIOLABS
  • TABLE 158 CREATIVE BIOLABS: COMPANY OVERVIEW
  • 13.1.15 PACBIO
  • TABLE 159 PACBIO: COMPANY OVERVIEW
  • FIGURE 42 PACBIO: COMPANY SNAPSHOT (2022)
• 13.2 OTHER PLAYERS
  • 13.2.1 HISTOGENETICS LLC
  • 13.2.2 SCISCO GENETICS, INC.
  • 13.2.3 INNO-TRAIN DIAGNOSTIK GMBH
  • 13.2.4 BIONOBIS
  • 13.2.5 QUEST DIAGNOSTICS
  • 13.2.6 SCIENCELL RESEARCH LABORATORIES, INC.
  • 13.2.7 BGI GENOMICS
  • 13.2.8 CEGAT GMBH
  • 13.2.9 PROIMMUNE LTD.
  • 13.2.10 CD GENOMICS
• *Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

관련자료